Metabolites (Mar 2024)

Exploring the Role of GDF-15 in Inflammatory Bowel Disease: A Case-Controlled Study Comparing Crohn’s Disease and Ulcerative Colitis with Non-Inflammatory Controls

  • Ondřej Kučerka,
  • Marie Blahutová,
  • Vít Kosek,
  • Petra Mináriková,
  • Jan M. Horáček,
  • Petr Urbánek,
  • Martin Malý

DOI
https://doi.org/10.3390/metabo14040185
Journal volume & issue
Vol. 14, no. 4
p. 185

Abstract

Read online

Inflammatory bowel disease, encompassing Crohn’s disease and ulcerative colitis, is a persistent immune-mediated inflammatory gastrointestinal disease. This study investigates the role of growth differentiation factor 15 in severe IBD cases, aiming to identify a reliable parameter to assess disease severity and monitor activity. We analyzed plasma samples from 100 patients undergoing biologic therapy for severe IBD and 50 control subjects. Our analysis included evaluations of GDF-15 levels, inflammatory markers, and clinical features. We employed statistical methods such as the Mann–Whitney U test, ANOVA, and Spearman’s correlation for an in-depth analysis. Our results demonstrated consistently higher GDF-15 levels in patients with both Crohn’s disease and ulcerative colitis compared to the control group, irrespective of the biologic treatment received. The correlation analysis indicated significant relationships between GDF-15 levels, patient age, fibrinogen, and IL-6 levels. This study positions GDF-15 as a promising biomarker for severe IBD, with notable correlations with age and inflammatory markers. These findings underscore GDF-15’s potential in enhancing disease monitoring and management strategies in an IBD context and encourage further research to clarify GDF-15’s role in the IBD pathophysiology.

Keywords